Luca Testa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9425283/publications.pdf

Version: 2024-02-01

212 papers 9,206 citations

44069 48 h-index 43889 91 g-index

236 all docs

236 docs citations

times ranked

236

7633 citing authors

#	Article	IF	CITATIONS
1	Transcatheter Aortic Valve Implantation in Failed Bioprosthetic Surgical Valves. JAMA - Journal of the American Medical Association, 2014, 312, 162.	7.4	762
2	A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease. European Heart Journal, 2006, 27, 2667-2674.	2.2	636
3	Transcatheter Aortic Valve Replacement for Degenerative Bioprosthetic Surgical Valves. Circulation, 2012, 126, 2335-2344.	1.6	528
4	Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus TricuspidÂAorticÂValve Stenosis. Journal of the American College of Cardiology, 2017, 69, 2579-2589.	2.8	356
5	Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25â€307 patients. European Heart Journal, 2006, 27, 519-526.	2.2	263
6	Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates. Journal of the American College of Cardiology, 2015, 65, 805-815.	2.8	248
7	Association Between Transcatheter Aortic Valve Replacement and Subsequent Infective Endocarditis and In-Hospital Death. JAMA - Journal of the American Medical Association, 2016, 316, 1083.	7.4	241
8	Transcatheter Aortic Valve Replacement inÂPure Native Aortic Valve Regurgitation. Journal of the American College of Cardiology, 2017, 70, 2752-2763.	2.8	207
9	A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease. American Heart Journal, 2008, 155, 274-283.	2.7	170
10	Delayed Coronary Obstruction After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2018, 71, 1513-1524.	2.8	170
11	Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition. QJM - Monthly Journal of the Association of Physicians, 2009, 102, 369-378.	0.5	151
12	Clinical Impact of Persistent Left Bundle-Branch Block After Transcatheter Aortic Valve Implantation With CoreValve Revalving System. Circulation, 2013, 127, 1300-1307.	1.6	141
13	Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. BMJ: British Medical Journal, 2006, 332, 202-209.	2.3	135
14	Is Bare-Metal Stent Implantation StillÂJustifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?. JACC: Cardiovascular Interventions, 2016, 9, 426-436.	2.9	135
15	Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. International Journal of Cardiology, 2011, 150, 325-331.	1.7	129
16	The Syntax score predicts peri-procedural myocardial necrosis during percutaneous coronary intervention. International Journal of Cardiology, 2009, 135, 60-65.	1.7	125
17	Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis. European Heart Journal, 2005, 26, 2000-2006.	2.2	120
18	Comparison of Incidence and Predictors of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation Using the CoreValve Versus the Edwards Valve. American Journal of Cardiology, 2013, 112, 554-559.	1.6	118

#	Article	IF	CITATIONS
19	A simple hint to improve Robinson and Dickersin's highly sensitive PubMed search strategy for controlled clinical trials. International Journal of Epidemiology, 2004, 34, 224-225.	1.9	117
20	Clinical impact and evolution of mitral regurgitation following transcatheter aortic valve replacement: a meta-analysis. Heart, 2015, 101, 1395-1405.	2.9	115
21	With the "Universal Definition,―Measurement of Creatine Kinase-Myocardial Band Rather Than Troponin Allows More Accurate Diagnosis of Periprocedural Necrosis and Infarction After Coronary Intervention. Journal of the American College of Cardiology, 2011, 57, 653-661.	2.8	114
22	Interplay Between Mitral Regurgitation and Transcatheter Aortic Valve Replacement With the CoreValve Revalving System. Circulation, 2013, 128, 2145-2153.	1.6	113
23	Interventionâ€â€Conflicts of interest: Ďr. Angiolillo is a consultant and on the speaker's bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami, Florida, and received lecture fees from Bristol Myers Squibb. Dr. Montalescot has been a consultant for and/or received	1.6	110
24	research grants from Sa. American Journal of Cardiology, 2007, 100, 1199-1206. Safety of a conservative strategy of permanent pacemaker implantation after transcatheter aortic CoreValve implantation. American Heart Journal, 2012, 163, 492-499.	2.7	107
25	Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. American Heart Journal, 2008, 155, 1081-1089.	2.7	105
26	Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves. European Heart Journal, 2020, 41, 2731-2742.	2.2	97
27	Meta-Analysis of the Impact of Mitral Regurgitation on Outcomes After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2015, 115, 942-949.	1.6	96
28	Transcatheter Mitral Valve Replacement After Surgical Repair or Replacement. Circulation, 2021, 143, 104-116.	1.6	94
29	Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: A metaregression. American Heart Journal, 2005, 149, 504-511.	2.7	90
30	CoreValve implantation for severe aortic regurgitation: a multicentre registry. EuroIntervention, 2014, 10, 739-745.	3.2	85
31	Outcomes in Patients With Transcatheter Aortic Valve Replacement and Left MainÂStenting. Journal of the American College of Cardiology, 2016, 67, 951-960.	2.8	83
32	Mid-Term Valve-Related Outcomes After Transcatheter Tricuspid Valve-in-Valve or Valve-in-Ring Replacement. Journal of the American College of Cardiology, 2019, 73, 148-157.	2.8	83
33	TAVR-Associated ProstheticÂValve InfectiveÂEndocarditis. Journal of the American College of Cardiology, 2014, 64, 2176-2178.	2.8	82
34	Transcatheter aortic valve implantation in patients with bicuspid aortic valve: A patient level multi-center analysis. International Journal of Cardiology, 2015, 189, 282-288.	1.7	82
35	Transcatheter Valve-in-Ring ImplantationÂfor the Treatment of ResidualÂor Recurrent Tricuspid Valve Dysfunction After Prior Surgical Repair. JACC: Cardiovascular Interventions, 2017, 10, 53-63.	2.9	81
36	Comparison of Results of Transcatheter Aortic Valve Implantation in Patients With Severely Stenotic Bicuspid Versus Tricuspid or Nonbicuspid Valves. American Journal of Cardiology, 2014, 113, 1390-1393.	1.6	79

#	Article	IF	CITATIONS
37	Adjunctive devices in primary or rescue PCI: A meta-analysis of randomized trials. International Journal of Cardiology, 2008, 123, 313-321.	1.7	78
38	Pexelizumab in ischemic heart disease: A systematic review and meta-analysis on 15,196 patients. Journal of Thoracic and Cardiovascular Surgery, 2008, 136, 884-893.	0.8	75
39	Tricuspid annuloplasty versus a conservative approach in patients with functional tricuspid regurgitation undergoing left-sided heart valve surgery: A study-level meta-analysis. International Journal of Cardiology, 2017, 240, 138-144.	1.7	64
40	Transcatheter Valve-in-Valve Implantation Using CoreValve Revalving System for Failed Surgical Aortic Bioprostheses. JACC: Cardiovascular Interventions, 2011, 4, 1228-1234.	2.9	62
41	Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-metal-stent-controlled trials. International Journal of Cardiology, 2005, 100, 119-123.	1.7	60
42	Intravascular ultrasound in the evaluation and treatment of left main coronary artery disease: a consensus statement from the European Bifurcation Club. EuroIntervention, 2018, 14, e467-e474.	3.2	60
43	Transcatheter Aortic Valve ReplacementÂWith Next-Generation Self-Expanding Devices. JACC: Cardiovascular Interventions, 2019, 12, 433-443.	2.9	59
44	Coronary Protection to Prevent Coronary Obstruction During TAVR. JACC: Cardiovascular Interventions, 2020, 13, 739-747.	2.9	58
45	Acute kidney injury after transcatheter aortic valve implantation with self-expanding CoreValve prosthesis: results from a large multicentre Italian research project. EuroIntervention, 2014, 10, 133-140.	3.2	55
46	The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. Expert Opinion on Drug Safety, 2007, 6, 397-406.	2.4	52
47	TAVI and Post Procedural Cardiac Conduction Abnormalities. Frontiers in Cardiovascular Medicine, 2018, 5, 85.	2.4	52
48	Clinical Valve Thrombosis After Transcatheter Aortic Valve-in-Valve Implantation. Circulation: Cardiovascular Interventions, 2018, 11, e006730.	3.9	51
49	Baseline and postoperative levels of C-reactive protein and interleukins as inflammatory predictors of atrial fibrillation following cardiac surgery: a systematic review and meta-analysis. Kardiologia Polska, 2018, 76, 440-451.	0.6	51
50	Haematological indices as predictors of atrial fibrillation following isolated coronary artery bypass grafting, valvular surgery, or combined procedures: a systematic review with meta-analysis. Kardiologia Polska, 2018, 76, 107-118.	0.6	50
51	Italian Society of Interventional Cardiology (<scp>Glse</scp>) registry Of Transcatheter treatment of mitral valve r <scp>egurgitaTiOn</scp> (<scp>GIOTTO</scp>): impact of valve disease aetiology and residual mitral regurgitation after <scp>MitraClip</scp> implantation. European Journal of Heart Failure, 2021, 23, 1364-1376.	7.1	49
52	Early Diagnosis of Perioperative Myocardial Infarction After Coronary Bypass Grafting: A Study Using Biomarkers and Cardiac Magnetic Resonance Imaging. Annals of Thoracic Surgery, 2011, 92, 2046-2053.	1.3	47
53	Impact of Balloon Post-Dilation on ClinicalÂOutcomes After Transcatheter Aortic Valve Replacement With the Self-Expanding CoreValve Prosthesis. JACC: Cardiovascular Interventions, 2014, 7, 1014-1021.	2.9	47
54	Transcatheter Mitral Valve Replacement in the Transcatheter Aortic Valve Replacement Era. Journal of the American Heart Association, 2019, 8, e013352.	3.7	46

#	Article	IF	CITATIONS
55	Adjusted Indirect Meta-Analysis of Aspirin Plus Warfarin at International Normalized Ratios 2 to 3 Versus Aspirin Plus Clopidogrel After Acute Coronary Syndromes. American Journal of Cardiology, 2007, 99, 1637-1642.	1.6	45
56	Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation. Circulation, 2017, 135, 2145-2154.	1.6	45
57	Long-term clinical outcome and performance of transcatheter aortic valve replacement with a self-expandable bioprosthesis. European Heart Journal, 2020, 41, 1876-1886.	2.2	45
58	A Score to Assess Mortality After Percutaneous Mitral Valve Repair. Journal of the American College of Cardiology, 2022, 79, 562-573.	2.8	44
59	Interaction between statins and clopidogrel: is there anything clinically relevant?. QJM - Monthly Journal of the Association of Physicians, 2008, 101, 915-925.	0.5	42
60	Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 949-957.	0.5	37
61	IntravaScular Lithotripsy for the Management of UndILatable Coronary StEnt: The SMILE Registry. Cardiovascular Revascularization Medicine, 2020, 21, 1555-1559.	0.8	37
62	Ximelagatran/melagatran against conventional anticoagulation: A meta-analysis based on 22,639 patients. International Journal of Cardiology, 2007, 122, 117-124.	1.7	36
63	Infective Endocarditis Following Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2019, 12, e007938.	3.9	36
64	Transcatheter Aortic Valve Implantation Under Angiographic Guidance With and Without Adjunctive Transesophageal Echocardiography. American Journal of Cardiology, 2015, 116, 604-611.	1.6	34
65	Persistence of Severe Pulmonary Hypertension After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	33
66	Cerebral Protection During Transcatheter Aortic Valve Implantation: An Updated Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2018, 7, .	3.7	33
67	Transcatheter mitral valve regurgitation treatment: State of the art and a glimpse to the future. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 319-327.	0.8	31
68	Safety and Efficacy of Polymer-Free Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2019, 12, e007311.	3.9	30
69	Unplanned Percutaneous Coronary Revascularization After TAVR. JACC: Cardiovascular Interventions, 2021, 14, 198-207.	2.9	30
70	Myocardial Injury following Coronary Artery Surgery versus Angioplasty (MICASA): a randomised trial using biochemical markers and cardiac magnetic resonance imaging. EuroIntervention, 2011, 6, 703-710.	3.2	30
71	Incidence, Technical Safety, and Feasibility of Coronary Angiography and Intervention Following Self-expanding Transcatheter Aortic Valve Replacement. Cardiovascular Revascularization Medicine, 2019, 20, 371-375.	0.8	29
72	Clinical performance of a novel sirolimus-coated balloon in coronary artery disease: EASTBOURNE registry. Journal of Cardiovascular Medicine, 2021, 22, 94-100.	1.5	29

#	Article	IF	CITATIONS
73	Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis. EuroIntervention, 2010, 6, 527-536.	3.2	29
74	Matched Comparison of Self-Expanding Transcatheter Heart Valves for the Treatment of Failed Aortic Surgical Bioprosthesis. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	28
75	Comparative one-month safety and effectiveness of five leading new-generation devices for transcatheter aortic valve implantation. Scientific Reports, 2019, 9, 17098.	3.3	28
76	Clinical, Angiographic, and Procedural Correlates of Acute, Subacute, and Late Absorb Scaffold Thrombosis. JACC: Cardiovascular Interventions, 2017, 10, 1809-1815.	2.9	26
77	One-year clinical outcome of amphilimus polymer-free drug-eluting stent in diabetes mellitus patients. International Journal of Cardiology, 2016, 214, 113-120.	1.7	25
78	Patterns and trends of transcatheter aortic valve implantation in Italy. Journal of Cardiovascular Medicine, 2017, 18, 96-102.	1.5	24
79	Impact of Routine Invasive Physiology atÂTime of Angiography in Patients WithÂMultivessel Coronary Artery DiseaseÂon Reclassification of Revascularization Strategy. JACC: Cardiovascular Interventions, 2018, 11, 354-365.	2.9	24
80	Real-World Safety and Efficacy of Transcatheter Mitral Valve Repair With MitraClip: Thirty-Day Results From the Italian Society of Interventional Cardiology (Glse) Registry Of Transcatheter Treatment of Mitral Valve RegurgitaTiOn (GIOTTO). Cardiovascular Revascularization Medicine, 2020, 21, 1057-1062.	0.8	23
81	Impact of Mitral Annular Calcium on Outcomes after Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2017, 120, 2233-2240.	1.6	22
82	Comparison of ProGlide vs. Prostar in patients undergoing transcatheter aortic valve implantation. Minerva Cardioangiologica, 2019, 67, 443-449.	1.2	22
83	Direct and indirect comparison meta-analysis demonstrates the superiority of sirolimus- versus paclitaxel-eluting stents across 5854 patients. International Journal of Cardiology, 2007, 114, 104-105.	1.7	21
84	Clinical, Angiographic, and ProceduralÂCorrelates of VeryÂLateÂAbsorbÂScaffoldÂThrombosis. JACC: Cardiovascular Interventions, 2018, 11, 638-644.	2.9	20
85	Intravascular lithotripsy in calcifiedâ€coronary lesions: A realâ€world observational, European multicenter study. Catheterization and Cardiovascular Interventions, 2021, 98, 225-235.	1.7	20
86	Surgical Treatment of Patients With Infective Endocarditis After Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2022, 79, 772-785.	2.8	20
87	Transcatheter aortic valve implantation in a patient with mechanical mitral prosthesis: A lesson learned from an intraventricular clash. Catheterization and Cardiovascular Interventions, 2013, 82, E621-5.	1.7	19
88	Impact of aortic angle on transcatheter aortic valve implantation outcome with Evolutâ€R, Portico, and Acurateâ€NEO. Catheterization and Cardiovascular Interventions, 2021, 97, E135-E145.	1.7	19
89	Temporal Trends, Characteristics, and Outcomes of Infective Endocarditis After Transcatheter Aortic Valve Replacement. Clinical Infectious Diseases, 2021, 73, e3750-e3758.	5.8	19
90	Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2021, 77, 2263-2273.	2.8	19

#	Article	IF	Citations
91	Right subclavian approach as a feasible alternative for transcatheter aortic valve implantation with the CoreValve ReValving System. EuroIntervention, 2012, 8, 685-690.	3.2	19
92	Drug-eluting balloon versus second-generation drug-eluting stent for the treatment of restenotic lesions involving coronary bifurcations. EuroIntervention, 2016, 11, 989-995.	3.2	19
93	Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: Rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in Uncertain DES Candidates study. American Heart Journal, 2013, 166, 831-838.	2.7	18
94	Emerging Technologies for Percutaneous Mitral Valve Repair. Frontiers in Cardiovascular Medicine, 2019, 6, 161.	2.4	18
95	Coronary Bioresorbable Vascular Scaffold Use in the Treatment of Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	17
96	Early Adverse Impact of Transfusion After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2020, 13, e009026.	3.9	17
97	Myocardial Perfusion Imaging After Coronary Artery Bypass Surgery Using Cardiovascular Magnetic Resonance. Circulation: Cardiovascular Imaging, 2011, 4, 312-318.	2.6	16
98	Polymer-free amphilimus-eluting stent versus biodegradable polymer biolimus-eluting stent in patients with and without diabetes mellitus. International Journal of Cardiology, 2017, 245, 69-76.	1.7	16
99	Cardiac magnetic resonance for ischaemia and viability detection. Guiding patient selection to revascularization in coronary chronic total occlusions: The CARISMA_CTO study design. International Journal of Cardiology, 2018, 272, 356-362.	1.7	16
100	The failing right heart: implications and evolution in high-risk patients undergoing transcatheter aortic valve implantation. EuroIntervention, 2016, 12, 1542-1549.	3.2	16
101	Outcomes of valve-in-valve transcatheter aortic valve implantation with and without bioprosthetic valve fracture. EuroIntervention, 2021, 17, 848-855.	3.2	16
102	Impact of Predilatation Prior to Transcatheter Aortic Valve Implantation With the Self-Expanding Acurate neo Device (from the Multicenter NEOPRO Registry). American Journal of Cardiology, 2020, 125, 1369-1377.	1.6	15
103	One-year clinical results of the Italian diffuse/multivessel disease ABSORB prospective registry (IT-DISAPPEARS). EuroIntervention, 2017, 13, 424-431.	3.2	15
104	Role of imaging in interventions on structural heart disease. Expert Review of Cardiovascular Therapy, 2013, 11, 1659-1676.	1.5	14
105	Is Transcatheter Aortic Valve Replacement Superior to Surgical Aortic Valve Replacement?. JACC: Cardiovascular Interventions, 2017, 10, 1899-1901.	2.9	14
106	Rapidly Evolving Giant Coronary Aneurysm. Journal of the American College of Cardiology, 2009, 53, 372.	2.8	13
107	Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents. Advances in Hematology, 2010, 2010, 1-7.	1.0	13
108	Residual Ischemia After Revascularization in Multivessel Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2013, 6, 237-245.	3.9	13

#	Article	IF	CITATIONS
109	Clinical outcomes of realâ€world patients treated with an amphilimus polymerâ€free stent versus new generation everolimusâ€eluting stents. Catheterization and Cardiovascular Interventions, 2015, 86, 1168-1176.	1.7	13
110	Unprotected left main revascularization: Percutaneous coronary intervention versus coronary artery bypass. An updated systematic review and meta-analysis of randomised controlled trials. PLoS ONE, 2017, 12, e0179060.	2.5	13
111	Transcatheter Aortic Valve Replacement for Degenerated Transcatheter Aortic Valves: The TRANSIT International Project. Circulation: Cardiovascular Interventions, 2021, 14, e010440.	3.9	13
112	Hybrid strategy with a bioresorbable scaffold and a drug-coated balloon for diffuse coronary artery disease: the "no more metallic cages―multicentre pilot experience. EuroIntervention, 2016, 11, e1589-e1595.	3.2	13
113	Long-Term Outcomes After Infective Endocarditis After Transcatheter Aortic Valve Replacement. Circulation, 2020, 142, 1497-1499.	1.6	13
114	Procedural and 30â€day clinical outcomes following transcatheter aortic valve replacement with lotus valve: Results of the RELEVANT study. Catheterization and Cardiovascular Interventions, 2017, 90, 1206-1211.	1.7	12
115	Transcatheter Aortic Valve Replacement Outcomes in Patients With Native vs Transplanted Kidneys: Data From an International Multicenter Registry. Canadian Journal of Cardiology, 2019, 35, 1114-1123.	1.7	12
116	Stroke Complicating Infective Endocarditis After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2021, 77, 2276-2287.	2.8	12
117	Transcatheter aortic valve implantation with the Portico and Evolut R bioprostheses in patients with elliptic aortic annulus. EuroIntervention, 2020, 15, e1588-e1591.	3.2	12
118	Systemic levels of endothelin correlate with systemic inflammation and not with myocardial injury or left ventricular ejection fraction in patients undergoing percutaneous coronary intervention and on-pump coronary artery bypass grafting. Interactive Cardiovascular and Thoracic Surgery, 2011, 13, 585-590.	1.1	11
119	Midterm and one-year outcome of amphilimus polymer free drug eluting stent in patients needing short dual antiplatelet therapy. Insight from the ASTUTE registry (AmphilimuS iTalian mUlticenTer) Tj ETQq1 1 0.	78 43 14 rş	gBT1/10verlock
120	Outcome of transcatheter aortic valve replacement in bicuspid aortic valve stenosis with new-generation devices. Interactive Cardiovascular and Thoracic Surgery, 2021, 32, 20-28.	1.1	11
121	Predictors of optimal procedural result after transcatheter edgeâ€toâ€edge mitral valve repair in secondary mitral regurgitation. Catheterization and Cardiovascular Interventions, 2022, 99, 1626-1635.	1.7	11
122	Perivalvular Extension of Infective Endocarditis After Transcatheter Aortic Valve Replacement. Clinical Infectious Diseases, 2022, 75, 638-646.	5.8	11
123	Directional atherectomy before stenting versus stenting alone in percutaneous coronary interventions: A meta-analysis. International Journal of Cardiology, 2006, 112, 178-183.	1.7	10
124	Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM trial. European Heart Journal, 2007, 28, 1782-1783.	2.2	10
125	Transcatheter aortic valve implantation in patients with severe aortic valve stenosis and large aortic annulus, using the self-expanding 31-mm Medtronic CoreValve prosthesis: First clinical experience. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 492-499.e1.	0.8	10
126	Transaxillary versus transaortic approach for transcatheter aortic valve implantation with CoreValve Revalving System: insights from multicenter experience. Journal of Cardiovascular Surgery, 2017, 58, 747-754.	0.6	10

#	Article	IF	Citations
127	A patientâ€specific algorithm to achieve commissural alignment with Acurate Neo: The sextant technique. Catheterization and Cardiovascular Interventions, 2021, 98, E847-E854.	1.7	10
128	What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. QJM - Monthly Journal of the Association of Physicians, 2010, 103, 367-377.	0.5	9
129	Italian Diffuse/Multivessel Disease ABSORB Prospective Registry (IT-DISAPPEARS). Study Design and Rationale. Journal of Cardiovascular Medicine, 2015, 16, 253-258.	1.5	9
130	SICI-GISE Position Document on the Use of the Magmaris Resorbable Magnesium Scaffold in Clinical Practice. Cardiovascular Revascularization Medicine, 2022, 34, 11-16.	0.8	9
131	Infective Endocarditis Caused by Staphylococcus aureus After Transcatheter Aortic Valve Replacement. Canadian Journal of Cardiology, 2022, 38, 102-112.	1.7	9
132	Acute worsening in migraine symptoms following PFO closure: A matter of fact?. International Journal of Cardiology, 2010, 144, 299-300.	1.7	8
133	Comparison of Early and Long-Term Outcomes After Transcatheter Aortic Valve Implantation in Patients with New York Heart Association Functional Class IV to those in Class III and Less. American Journal of Cardiology, 2018, 122, 1718-1726.	1.6	8
134	Impact of Predilation Before Transcatheter Aortic Valve Implantation with New-Generation Devices. Cardiovascular Revascularization Medicine, 2019, 20, 1096-1099.	0.8	8
135	Interaction between severe chronic kidney disease and acute kidney injury in predicting mortality after transcatheter aortic valve implantation: Insights from the Italian Clinical Service Project. Catheterization and Cardiovascular Interventions, 2020, 96, 1500-1508.	1.7	8
136	Selection of the Optimal Candidate to MitraClip for Secondary Mitral Regurgitation: Beyond Mitral Valve Morphology. Frontiers in Cardiovascular Medicine, 2021, 8, 585415.	2.4	8
137	First-in-human evaluation of a novel sirolimus-eluting ultra-high molecular weight APTITUDE bioresorbable scaffold: 9- and 24-month imaging and clinical results of the RENASCENT II trial. EuroIntervention, 2020, 16, e133-e140.	3.2	8
138	Prognostic significance of right ventricle to pulmonary artery coupling in patients with mitral regurgitation treated with the MitraClip system. Catheterization and Cardiovascular Interventions, 2022, 99, 1277-1286.	1.7	8
139	A multi-center, international, randomized, 2-year, parallel-group study to assess the superiority of IVUS-guided PCI versus qualitative angio-guided PCI in unprotected left main coronary artery (ULMCA) disease: Study protocol for OPTIMAL trial. PLoS ONE, 2022, 17, e0260770.	2.5	8
140	Multi-Link Vision stent vs. first-generation drug-eluting stents: systematic review and meta-analysis. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 1025-1034.	0.5	7
141	Sex based analysis of the impact of red blood cell transfusion and vascular or bleeding complications related to TAVI – The TRITAVI-Women Study. International Journal of Cardiology, 2021, 333, 69-76.	1.7	7
142	Assessing the Risk of Leaflet Motion Abnormality Following Transcatheter Aortic Valve Implantation. Interventional Cardiology Review, 2017, 13, 1.	1.6	7
143	Oneâ€Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimusâ€Eluting Stents in High Bleeding Risk Patients. Journal of the American Heart Association, 2022, 11, e023454.	3.7	7
144	Italian Multicenter Registry of Bare Metal Stent Use in Modern Percutaneous Coronary Intervention Era (AMARCORD): A multicenter observational study. Catheterization and Cardiovascular Interventions, 2021, 97, 411-420.	1.7	6

#	Article	IF	Citations
145	Bioprosthetic valve fracture: Predictors of outcome and <scp>followâ€up</scp> . Results from a multicenter study. Catheterization and Cardiovascular Interventions, 2021, 98, 756-764.	1.7	6
146	Very early infective endocarditis after transcatheter aortic valve replacement. Clinical Research in Cardiology, 2022, 111, 1087-1097.	3.3	6
147	Repeat thrombolysis or conservative therapy vs. rescue percutaneous coronary intervention for failed thrombolysis: systematic review and meta-analysis. QJM - Monthly Journal of the Association of Physicians, 2008, 101, 387-395.	0.5	5
148	Prognostic Significance of Small Troponin I Rise After a Successful Elective Percutaneous Coronary Intervention of a Native Artery. American Journal of Cardiology, 2009, 103, 1622-1623.	1.6	5
149	Transcatheter Aortic Valve-in-Valve Implantation Using Lotus Valve for FailedÂSurgical Bioprostheses. Annals of Thoracic Surgery, 2017, 104, 638-644.	1.3	5
150	Oneâ€year safety and efficacy profile of transcatheter aortic valveâ€inâ€valve implantation with the portico system. Catheterization and Cardiovascular Interventions, 2021, 98, E145-E152.	1.7	5
151	Bailout From Sinus Jailing. JACC: Case Reports, 2021, 3, 678-681.	0.6	5
152	Severe Valvular Heart Disease and COVID-19: Results from the Multicenter International Valve Disease Registry. Structural Heart, 2021, 5, 424-426.	0.6	5
153	Merging the properties of a sirolimus coated balloon with those of a bioresorbable polymer sirolimus eluting stent to address the "diabetes issue". Results from the En-Abl multicenter registry. Minerva Cardioangiologica, 2018, 66, 536-542.	1.2	5
154	In-hospital outcomes and predictors of paravalvular leak and deep implantation with the Evolut-R 34 mm device: A comparison with smaller Evolut-R sizes. Cardiovascular Revascularization Medicine, 2021, 35, 19-19.	0.8	4
155	Rate-control or rhythm-control: where do we stand?. Indian Pacing and Electrophysiology Journal, 2005, 5, 296-304.	0.6	4
156	Increased mortality after coronary stenting in patients treated with clopidogrel without loading dose. Evidence from a meta-analysis. Minerva Cardioangiologica, 2004, 52, 195-208.	1.2	4
157	A practical algorithm for systematic reviews in cardiovascular medicine. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2004, 5, 486-7.	0.1	4
158	Durability of Surgical and Transcatheter Aortic Bioprostheses: A Review of the Literature. Cardiovascular Revascularization Medicine, 2022, 42, 161-170.	0.8	4
159	Transcatheter aortic valve replacement—state of the art and a glimpse to the future: â€~the Tailored Approach'. European Heart Journal Supplements, 2016, 18, E86-E95.	0.1	3
160	Two-year clinical outcomes of the "ltalian diffuse/multivessel disease absorb prospective registry― (IT-DISAPPEARS). International Journal of Cardiology, 2019, 290, 21-26.	1.7	3
161	Clinical impact and evolution of mitral regurgitation after TAVI using the new generation self-expandable valves. International Journal of Cardiology, 2021, 335, 85-92.	1.7	3
162	Pexelizumab and survival in cardiac surgery. HSR Proceedings in Intensive Care & Cardiovascular Anesthesia, 2011, 3, 23-4.	0.6	3

#	Article	IF	CITATIONS
163	Mitral Valve Infective Endocarditis after Trans-Catheter Aortic Valve Implantation. American Journal of Cardiology, 2022, 172, 90-97.	1.6	3
164	Sex Differences in Infective Endocarditis After Transcatheter Aortic Valve Replacement. Canadian Journal of Cardiology, 2022, 38, 1418-1425.	1.7	3
165	Low-Dose Aspirin for Stroke Prevention. Stroke, 2006, 37, 1356-1356.	2.0	2
166	Letter by Testa et al Regarding Article, "Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization― Circulation, 2007, 116, e549; author reply e550.	1.6	2
167	Letters to the Editor. Journal of Thoracic and Cardiovascular Surgery, 2007, 134, 816-817.	0.8	2
168	Intravascular Ultrasound Determinants of Future Coronary Stent Thrombosis. American Journal of Cardiology, 2008, 101, 743-744.	1.6	2
169	Comment on 'Comparison of operator radiation exposure with optimized radiation protection devices during coronary angiograms and ad hoc percutaneous coronary interventions by radial and femoral routes'. European Heart Journal, 2008, 29, 2820-2821.	2.2	2
170	ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome. European Heart Journal Supplements, 2014, 16, C2-C28.	0.1	2
171	Transcatheter aortic valve implantation in patients younger than 75†years: Guidelines-based patients selection and clinical outcome. International Journal of Cardiology, 2018, 272, 273-278.	1.7	2
172	XLIMus drug eluting stent: A randomIzed controlled Trial to assess endothelialization. The XLIMIT trial. IJC Heart and Vasculature, 2019, 23, 100363.	1.1	2
173	Diagnostic Accuracy of Microcatheter Derived Fractional Flow Reserve. American Journal of Cardiology, 2019, 124, 183-189.	1.6	2
174	Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. International Journal of Cardiology, 2019, 277, 60-65.	1.7	2
175	Targeting "diabetic" coronary artery disease merging the properties of sirolimus coated balloon with sirolimus eluting stent. Minerva Cardiology and Angiology, 2021, 69, 525-532.	0.7	2
176	How should I treat a coronary "traffic jam� A triple kissing balloon in distal left main trifurcation. EuroIntervention, 2011, 6, 1011-1016.	3.2	2
177	The impact of the use of bioresorbable vascular scaffolds and drug-coated balloons in coronary bifurcation lesions. Egyptian Heart Journal, 2019, 71, 31.	1.2	2
178	Long-term outcomes after transcatheter aortic valve replacement in nonagenarians: a multicenter age-based analysis. Journal of Cardiovascular Medicine, 2021, 22, 204-211.	1.5	2
179	The Hurdles of Warfarin and the Hurdles of Clinical Practice. Stroke, 2006, 37, 2867-2867.	2.0	1
180	Perspectives on patients with diabetes mellitus and triple-vessel disease undergoing coronary artery bypass grafting after previous percutaneous coronary intervention. Journal of Thoracic and Cardiovascular Surgery, 2008, 135, 1400.	0.8	1

#	Article	IF	CITATIONS
181	The new era of oral anticoagulation: the 'finger pointing to the moon is not the moon' Reply to: Differences between indirect comparison studies of the oral anticoagulants for stroke prevention in atrial fibrillation: where do we go next? By Job Harenberg, Gregory Y.H. Lip. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 96-97.	0.5	1
182	Bioresorbable Vascular Scaffolds as a Treatment Option for Left Main Lesions. JACC: Cardiovascular Interventions, 2017, 10, 743-745.	2.9	1
183	TCT-34 Bioprosthetic Valve Fracture Can Eliminate Pre-Existing Prothesis-Patient Mismatch. Journal of the American College of Cardiology, 2019, 74, B34.	2.8	1
184	ImpaCt of an Optimal Implantation Strategy on Absorb Long-Term Outcomes: The CIAO Registry. Cardiovascular Revascularization Medicine, 2021, 30, 1-8.	0.8	1
185	RENASCENT III: First in Human Evaluation of the Novel Thin Strut MAGNITUDE Sirolimus-Eluting Ultra-High Molecular Weight MAGNITUDE Bioresorbable Scaffold: 9-Month Imaging and 2-Year Clinical Results. Circulation: Cardiovascular Interventions, 2021, 14, e010013.	3.9	1
186	Transcatheter Aortic Valve Implantation for Pure Aortic Regurgitation., 2019,, 515-520.		1
187	From Chaotic to Coordinated Clinical Research: The Case of Acetylcysteine. Archives of Internal Medicine, 2006, 166, 1668.	3.8	0
188	Ximelagatran Versus Warfarin in the Prevention of Atrial Fibrillation–Related Stroke: Both Sides of the Story. Stroke, 2007, 38, e57.	2.0	0
189	Plaque Burden, Intravascular Ultrasound, and Distal Embolization Phenomenon. Journal of the American College of Cardiology, 2008, 51, 1323-1324.	2.8	0
190	The Hurdles of Translating a Single-Center Observation Into Practice. Archives of Internal Medicine, 2008, 168, 1719.	3.8	0
191	Nonconventional use of coronary guidewires for ECG recording and emergency pacing. Journal of Cardiovascular Medicine, 2008, 9, 1222-1228.	1.5	0
192	Letter by Testa et al Regarding Article, "Presence of Older Thrombus Is an Independent Predictor of Long-Term Mortality in Patients With ST-Elevation Myocardial Infarction Treated With Thrombus Aspiration During Primary Percutaneous Coronary Intervention― Circulation, 2009, 120, e3; author reply e5.	1.6	0
193	Selection of Medications to Prevent Stroke Among Individuals With Atrial Fibrillation. Current Treatment Options in Neurology, 2013, 15, 583-592.	1.8	0
194	Response to Letter Regarding Article, "Clinical Impact of Persistent Left Bundle-Branch Block After Transcatheter Aortic Valve Implantation With CoreValve Revalving System― Circulation, 2013, 128, e444.	1.6	0
195	Outcomes After Transcatheter Aortic Valve Replacement WithÂBalloon-Expandable Versus Self-Expandable Valves. Journal of the American College of Cardiology, 2016, 67, 235-236.	2.8	0
196	Patient selection and percutaneous technique of unprotected left main revascularization. Catheterization and Cardiovascular Interventions, 2018, 92, 637-643.	1.7	0
197	TCT-549 Long-term Clinical Outcomes after Implantation of Novel Abluminal Coated Sirolimus Eluting Stent in Real World Unselected Population: Update from en-ABL e-Registry. Journal of the American College of Cardiology, 2018, 72, B221.	2.8	0
198	P1676Safety and efficacy of trans-subclavian aortic valve implantation in obese patients: a propensity-matched cohort of trans-subclavian versus trans-femoral approach. European Heart Journal, 2018, 39, .	2.2	0

#	Article	IF	Citations
199	Abstracting Evidence., 2018,, 93-98.		O
200	CRT-700.30 Cerebral Protection During Transcatheter Aortic Valve Implantation: An Updated Systematic Review and Meta-analysis. JACC: Cardiovascular Interventions, 2018, 11, S56.	2.9	0
201	TCTAP A-137 Prosthesis-related Events Throughout 10 Years After TAVI. Journal of the American College of Cardiology, 2019, 73, S71-S72.	2.8	0
202	LONG TERM CLINICAL OUTCOME OF A NOVEL SIROLIMUS-ELUTING CORONARY STENT WITH UNIQUE COATING TECHNOLOGY IN PATIENTS WITH DIABETES. Journal of the American College of Cardiology, 2019, 73, 1157.	2.8	0
203	TCTAP A-005 Prosthesis Durability Throughout 10 Years After TAVI. Journal of the American College of Cardiology, 2019, 73, S2.	2.8	0
204	P2806A novel sirolimus drug eluting stent for Small-Vessel Disease: results from en-ABL e-registry. European Heart Journal, 2019, 40, .	2,2	0
205	CRT-100.93 To Evaluate Safety and Efficacy of Novel Sirolimus-Eluting Stent (DES+DCB) and Sirolimus-Coated Balloon for Treatment of Patients With Diabetes Mellitus. JACC: Cardiovascular Interventions, 2020, 13, S26.	2.9	0
206	Improved transfemoral accessibility and positioning of the Portico transcatheter heart valve with the new FlexNav delivery system. Future Cardiology, 2021, 17, 619-624.	1.2	0
207	Long-term outcomes of percutaneous or surgical treatment in left main disease: the never-ending story. Minerva Cardiology and Angiology, 2021, 69, 310-312.	0.7	0
208	Treatment of saphenous vein graft disease: "Never ending story―of the "eternal return― Research in Cardiovascular Medicine, 2014, 3, 5.	0.1	0
209	Techniques and Devices. , 2017, , 33-65.		0
210	Leaflet Motion Abnormality Following Transcatheter Aortic Valve Implantation. , 2019, , 183-188.		0
211	Acute changes in mitral valve geometry after MitraClip procedure assessed by 3D transoesophageal echocardiography. European Heart Journal, 2020, 41, .	2.2	0
212	Transcatheter treatment of tricuspid and mitral regurgitation. Similar path, different stages. Cardiovascular Revascularization Medicine, 2021, , .	0.8	0